x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001122
| Product Overview | |
|---|---|
| Species | Human |
| Expression System | Baculovirus infected Sf9 cells |
| Format | Liquid |
| Purity | ≥ 98% |
| Nature | Recombinant |
| Target Information | |
|---|---|
| Gene Name | AKT2 |
| UniProt No. | P31751 |
| Gene ID | 208 |
| Alternative Names | Akt2; AKT2_HUMAN; HIHGHH; Murine thymoma viral (v-akt) homolog 2; murine thymoma viral (v-akt) homolog-2; Oncogene AKT2 protein kinase B beta; PKB; PKB beta; PKBB; PKBBETA; PRKBB; Protein kinase Akt 2; Protein kinase Akt-2; Protein kinase B beta; RAC beta; rac protein kinase beta; RAC-BETA; RAC-beta serine/threonine-protein kinase; RAC-PK-beta; RACbeta; v akt murine thymoma viral oncogene homolog 2; V-AKT murine thymoma viral oncogene homolog 2 |
| Function | General protein kinase capable of phosphorylating several known proteins. |
| Protein Length | Full length protein |
| Sequence | MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLP PLNNFSVAEC;QLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREE WMRAIQMVANSLKQRAPGEDPM;DYKCGSPSDSSTTEEMEVAVSKARAK VTMNDFDYLKLLGKGTFGKVILVREKATGRYYAM;KILRKEVIIAKDEV AHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFH;LS RERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKIT DFGLCKEG;ISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVM YEMMCGRLPFYNQDHERLFE;LILMEEIRFPRTLSPEAKSLLAGLLKKD PKQRLGGGPSDAKEVMEHRFFLSINWQDVVQK;KLLPPFKPQVTSEVDT RYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIR;E,Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily. Contains 1 AGC-kinase C-terminal domain. Contains 1 PH domain. Contains 1 protein kinase domain. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
